10 December 2024: The National Institute for Health and Care Excellence (NICE) has approved vamorolone (Agamree, Santhera) as a treatment option for Duchenne Muscular Dystrophy (DMD) in individuals aged 4 years and over, following a revised pricing agreement with the manufacturer. Despite initial rejection in March due to uncertainties in evidence and cost-effectiveness, further analyses…
© 2024 ACNR. Published by Whitehouse Publishing. Read our Privacy and Cookie Policy. Website by Sugar Web.
Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified.
For UK-based specialists, sign up for our journal mailing list.
URL here
You are now leaving the ACNR website, please click the "Continue" button below. If you do not wish to leave, please close this pop-up.